Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…experienced severe reactions. The five most reported drugs were nivolumab (92,753; 44.4%), pembrolizumab (62,096; 29.7%), atezolizumab (3…
…=33 non-small cell lung cancer and n=2 small cell) treated with Pembrolizumab, Nivolumab or Durvalumab, either alone or in conjunction with c…
…cating an additional mechanism of action for PK-E1 like that of pembrolizumab (Keytruda) and nivolumab (Opdivo).Conclusions As novel bispecif…
…ansen JS, Larsen FO, Theile S, Hasselby JP, Willemoe GL, et al. Nivolumab with or without ipilimumab combined with stereotactic body radi…
…stman H, Gill AJ, et al. Retrospective evaluation of the use of pembrolizumab in malignant mesothelioma in a real-world Australian population…
…g immunosuppressive regimens comprising various combinations of sirolimus, everolimus, prednisone, cellcept, cyclosporine, tacrolimus, be…
…den, survival, DNA-damage, immune infiltration, and response to pembrolizumab was assessed.Results A prefoldin protein, previously reported a…
…an age was 63.8 years. The most common first-line regimens were nivolumab (N) + cabozantinib (44.1%), N + ipilimumab (26.5%), pembrolizum…
…Chevreau C, Penel N, Bertucci F, Toulmonde M, Bellera C, et al. Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a ph…
…ed T cell expansion in pre-therapy patient samples treated with pembrolizumab. In mice bearing neddylation-deficient breast EO771 tumors, PD-…
…herapy, and 56.7% were stage IV at diagnosis. Patients received nivolumab (10%), pembrolizumab (70%), or ipilimumab/nivolumab combination…
…(11):2835–2843. doi: 10.1038/s41591-023-02583-2.Luke JJ, et al, Pembrolizumab versus placebo as adjuvant therapy in completely resected stage…